Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib

Abstract

To evaluate and compare the health-related quality of life (HRQOL) of patients with newly diagnosed CML in the first chronic phase (CML-CP1) receiving HLA-identical sibling donor (ISD) hematopoietic SCT (HSCT) or imatinib, a cross-sectional study that was part of a prospective cohort study at the Institute of Hematology, Peking University was performed. A total of 222 patients including 126 and 96 in the imatinib and ISD HSCT groups, respectively, were enrolled. HRQOL was measured using the Medical Outcomes Study 36-Item Short-Form Health Survey. The ISD HSCT group functioned significantly better on the role-physical functioning and mental health subscales, as well as the mental component summary (MCS) than the imatinib group. HRQOL was generally comparable to groups in the young population. Multivariate analysis showed that white blood cell countX30 Â 10 9 /L and plts count X450 Â 10 9 /L were the major adverse factors affecting HRQOL in long-term survivors. Imatinib therapy was also an adverse factor affecting the MCS (odds ratio ¼ 1.7, P ¼ 0.032). Thus, long-term CML-CP1 survivors receiving ISD HSCT can attain desirable HRQOL comparable to or better than that of patients receiving imatinib.

Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia

“…It is also notable that the Physical and Mental Component Summary Scores were comparable to those in the U.S. general population (~50). 14 …”

Fear of Progression in Outpatients With Chronic Myeloid Leukemia on Oral Tyrosine Kinase Inhibitors

“…Data on distress in outpatients diagnosed with CML are scarce. To the authors' knowledge, fear of progression (FoP) in the context of CML was only mentioned in a single Chinese report (Mo et al, 2014) and was not conceptualized or specifically investigated. Mo et al (2014) only assumed that FoP was present and possibly related to incalculable costs of lifelong medication, which are not covered by the local health system.…”

The role of hematopoietic stem cell transplantation in chronic myeloid leukemia

“…Survival of patients under drug treatment with advanced disease in parallel was substantially better for those treated in a University affiliated center compared to those in a community practice [63]. And, there are no hints that quality of life is worse after HSCT for long term survivors [64,65]. Some consequences could be drawn.…”